Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 4/20 | 0.36 |
| ▸ | ATR | Q13535 | 4/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30068131 | 1.00 | FYN (0.39) | FYNTP53P2RX3P2RX2ATM | |
| SCHEMBL30068268 | 0.81 | FYN (0.50) | FYNTP53P2RX3P2RX2POLB | |
| SCHEMBL26646776 | 0.81 | FYN (0.50) | FYNTP53P2RX3P2RX2POLB | |
| SCHEMBL30829003 | 0.79 | FYN (0.39) | FYNTP53P2RX3P2RX2POLB | |
| SCHEMBL26646913 | 0.79 | FYN (0.39) | FYNTP53P2RX3P2RX2POLB | |
| SCHEMBL26805066 | 0.78 | NOS3 (0.47) | ATMATRGSK3BPRKDC | |
| SCHEMBL26647445 | 0.77 | MAPT (0.50) | FYNTP53POLBTSHRMAPK1 | |
| SCHEMBL26646891 | 0.75 | FYN (0.37) | FYNTP53POLBTSHRMAPK1 | |
| SCHEMBL30828948 | 0.75 | FYN (0.37) | FYNTP53POLBTSHRMAPK1 | |
| SCHEMBL26771681 | 0.73 | MAPT (0.51) | POLBTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022240876-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | FYN 647/4885TP53 273/4885P2RX3 3692/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | FYN 647/4885TP53 273/4885P2RX3 3692/4885 |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | FYN 647/4885TP53 273/4885P2RX3 3692/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | FYN 647/4885TP53 273/4885P2RX3 3692/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | FYN 664/4885TP53 270/4885P2RX3 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.